BioCardia, Inc. (BCDA) vs Lipocine Inc. (LPCN)

A side-by-side comparison of BioCardia, Inc. and Lipocine Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BCDA vs LPCN

growth of $100 · dividends reinvested · last 10y
BCDA -99.8% (-46.2%/yr)LPCN -97.2% (-30.0%/yr)LPCN compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $10020182020202220242026$0$3
BCDA LPCN

BCDA vs LPCN: by the numbers

  • •LPCN is the larger company ($17M vs $16M market cap).
  • •Both run net losses; BCDA's is the smaller (0.00% vs -755.13% net margin).

Metrics side by side

Valuation

MetricBCDALPCN
P/S ratioN/A10.95
P/B ratio6.090.79

Profitability

MetricBCDALPCN
Gross margin0.00%-334.26%
Operating margin0.00%-524.69%
Net margin0.00%-755.13%
ROE-271.81%-54.45%
ROIC-273.70%-57.74%

Growth (annualized)

MetricBCDALPCN
Total return CAGR (5Y)-61.39%-34.76%

Frequently asked

How have BCDA and LPCN total returns compared?
Over the past 10 years, BCDA delivered -46.74% and LPCN delivered -29.99% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.